Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder
JournalInternational Journal of Neuropsychopharmacology
PublisherOxford University Press
MetadataShow full item record
AbstractBackground: This randomized, placebo-controlled, crossover trial examined the antidepressant efficacy of the muscarinic antagonist scopolamine in major depressive disorder subjects with more severe and refractory forms of major depressive disorder relative to previous reports. Methods: Participants included 23 medication-free major depressive disorder subjects (12 F/11 M, 20-55 years) currently experiencing a major depressive episode. Subjects had scored ?20 on the Montgomery-Asberg Depression Rating Scale. Following a single-blind, placebo lead-in, participants were randomized to receive 2 counterbalanced blocks of 3 i.v. infusions of scopolamine (4 ?g/kg) and placebo in a double-blind manner. The primary and secondary outcomes were the Montgomery- Asberg Depression Rating Scale and the Hamilton Anxiety Rating Scale, respectively. Magnetoencephalography and plasma brain-derived neurotrophic factor concentrations were obtained prior to and after each treatment phase. Results: As assessed by both the Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Rating Scale, scopolamine had no significant antidepressant or anxiolytic effects relative to placebo. No significant drug vs placebo effects were seen in magnetoencephalography gamma power or brain-derived neurotrophic factor plasma concentrations, and brain-derived neurotrophic factor changes did not correlate with change in Montgomery-Asberg Depression Rating Scale score in response to scopolamine. Conclusions: These results do not support the efficacy of scopolamine for more severe or refractory forms of depression. No pre- to post-infusion changes in plasma brain-derived neurotrophic factor were detected, and magnetoencephalography gamma power changed only in the placebo lead-in, suggesting that these biomarker measures were not affected by scopolamine in this cohort. While difficult to interpret given the lack of antidepressant response, the findings suggest that the neurobiological effects of ketamine and scopolamine are at least partly distinct. Copyright 2018 The Author(s).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85057790880&doi=10.1093%2fijnp%2fpyy051&partnerID=40&md5=fe469d9ac02a6b43244f58468f8d8af8; http://hdl.handle.net/10713/9410
- Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
- Authors: Furey ML, Drevets WC
- Issue date: 2006 Oct
- Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
- Authors: Furey ML, Khanna A, Hoffman EM, Drevets WC
- Issue date: 2010 Nov
- Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
- Authors: Gilbert JR, Yarrington JS, Wills KE, Nugent AC, Zarate CA
- Issue date: 2018 Aug 1
- Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
- Authors: Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA Jr, Shugart YY
- Issue date: 2018 Dec 14
- A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
- Authors: Chen JCC, Sumner RL, Krishnamurthy Naga V, Hoeh N, Ayeni HA, Singh V, Sundram F, Campbell D, Muthukumaraswamy S
- Issue date: 2020 Feb 10